Vijaypd Ceutical IPO

About Vijaypd Ceutical IPO

The Vijaypd Ceutical Ltd IPO comprises a fresh issue of up to 55,00,000 equity shares, aggregating up to ₹19.25 crores. There’s no offer for sale in this IPO which is a 100% fixed-price issue. The price band is ₹35 per share. The IPO opens on September 29, 2025 and closes on October 1, 2025.

The listing date is on October 7, 2025 and the allotment date is on October 3, 2025. The credit of shares to the Demat account will take place on October 6, 2025, while the initiation of refund will take place on October 6, 2025.

Vijaypd Ceutical Ltd is engaged in the business of distribution and supply within the pharmaceutical and consumer goods sectors, offering a comprehensive range of services. Its role includes being representatives, dealers, agents, stockists, suppliers, traders, and packers. It offers a wide range of products serving both the pharmaceutical and wellness industries, as well as the fast-moving consumer goods (FMCG) market.

Objectives of Vijaypd Ceutical IPO

• Funding of capital expenditure requirements of the company towards the construction of pharmaceutical API/ intermediates and chemicals manufacturing plant and purchase of machineries in MIDC, Maharashtra
  
• Repayment/prepayment of all or certain of borrowings availed of by the company
  
• General corporate purposes
  

Industry Outlook

The Indian pharmaceutical industry is ranked as the third largest in the world, in terms of volumes of drugs manufactured and thirteenth largest, in terms of value. The country is also the world’s largest supplier of cost-effective generic drugs, and accounts for nearly one fifth of the global trade in generic drugs. India has achieved an enviable position in the global generic drug market on the back of its strength in organic chemical synthesis and process engineering.

Today India accounts for nearly 60% of the global vaccine production. This includes nearly 70% of WHO demand for vaccines to combat Diphtheria, Tetanus, Pertussis and BCG vaccine as well as nearly 90% of measles vaccine demand.

The global dominance of the Indian pharmaceutical industry, primarily in generic formulation space is set to continue in the foreseeable future. The patent cliff which lifted the patent protection of numerous blockbuster drugs has been a major enabler in the growth of formulations.

Indian firms have been able to capitalise on the patent cliff by the timely launch of generic versions in the US market. Based on the expected developments, the annual revenue turnover in the pharmaceutical industry is expected to reach ₹7300 Bn by FY 2030, growing by a CAGR of 10% during FY 2024-30.

Company Information

Vijaypd Ceutical Ltd is engaged in the business of distributor and supplier of the pharmaceutical products and consumer goods sectors, offering a comprehensive range of services. Its role includes being representatives, dealers, agents, stockists, suppliers, traders, and packers.

It provides a wide range of products, serving both the pharmaceutical and wellness industries, as well as the fast-moving consumer goods (FMCG) market. This includes pharmaceutical and wellness products such as medicines, including injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral products, vitamins, hormones, enzymes, and wellness tonics, serums and diagnostic test kits.

It also offers fast-moving consumer goods, such as personal care and toiletries like soaps, sanitisers, and baby care items, ayurvedic products, cosmetics and food products. Additionally, it provides dental products and crude drugs.

Strengths of Vijaypd Ceutical IPO

• Strong market position that increases the long-term relationship with the clients
  
• Comprehensive product portfolio
  
• Experienced management team with proven execution capabilities
  
• Streamlined supply chain management
  

Risks of Vijaypd Ceutical IPO

• The company may incur losses if customers return products due to the distribution of expired, unsafe, defective, ineffective, or counterfeit products
  
• Any adverse developments in Maharashtra could adversely affect business, results of operations, cash flows and financial condition
  
• Any downturn in the pharmaceutical industry could have an adverse impact on the company’s business and results of operations
  
• Inability to identify expansion opportunities may adversely impact business, financial condition and results of operation
  
• No long-term agreements with customer, which could adversely impact business
  

Anchor Investor Bidding Date

The anchor investor bidding date is Sep 26, 2025.

IPO Registrar and Book Running Lead Manager

• IPO Registrar: Kfin Technologies Ltd
• Book Running Lead Manager: Smart Horizon Capital Advisors Private Limited

Business Model

The primary line of business of Vijaypd Ceutical Ltd is in the distribution of healthcare products to retail pharmacies, nursing homes and healthcare clinics in Maharashtra. Its ancillary lines of business are comprehensive and integrated commercial solutions, including sales, marketing and supply chain solutions to pharmaceutical companies and healthcare product manufacturers.

Company Growth Trajectory

The revenue from operations of Vijaypd Ceutical Ltd grew from ₹48.7688 crores in FY 23 to ₹106.8101 crores in FY 25 while its EBITDA margin grew from 2.70% in FY 23 to 8.04% in FY 25. The company’s PAT margin grew from 0.37% in FY 23 to 4.49% in FY 25. Its diverse portfolio coupled with robust last-mile delivery infrastructure and good relationships with healthcare providers has contributed to the company’s growth.

Market Position

Operating three distribution warehouses located across Mumbai, ensuring timely and efficient deliveries, as of September 30, 2024, the customer base of Vijaypd Ceutical Ltd includes over 1,451 pharmacies, clinics, and nursing homes across three districts, covering 20 locations.

Its distribution network is supported by connecting with more than 154 healthcare product manufacturers, granting its access to a diverse range of over 24,000 product stock-keeping units. It’s one of the oldest pharmaceutical distributors in western Mumbai.

How to Check Allotment Status of Vijaypd Ceutical IPO?

Visit the Registrar’s Website

• Visit the official website of Kfin Technologies Ltd
• Click on ‘IPO Allotment Status’ from ‘Investors’ under ‘Products’ dropdown
• Click on any one of the links
• Select the IPO name and enter either application number, PAN or Demat account number
• Enter captcha and click on ‘Submit’ to know the status

Check on the National Stock Exchange Website

The National Stock Exchange (NSE) has an IPO Bid Verification module. You can use it to check the status of Vijaypd Ceutical Ltd IPO. Go to www.nseindia.com and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'.

On the NSE IPO Bid Verification page, enter:

• Company name from dropdown
• Application number
• PAN Then click 'Submit' to know the allotment status.

How to Apply for Vijaypd Ceutical IPO?

• Step 1: Log in to your Kotak Securities Demat account: Log in to your Demat account to access IPO investments. Next, select the current IPO section.
  
• Step 2: Specify IPO details: Enter the number of lots and the price you wish to apply for.
  
• Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.
  
• Step 4: Mandate Notification: Your UPI app will receive a mandate notification to block funds.
  
• Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.